title: Over-expression of CCL3 MIP-1alpha in a blastoid mantle cell lymphoma with hypercalcemia.
abstract: We analyzed a case with the blastoid variant of mantle cell lymphoma (MCL-BV), a rare subtype of B-cell lymphoma, presenting with marked hypercalcemia at diagnosis. Enzyme-linked immunosorbent assay (ELISA) showed elevated serum levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), macrophage inflammatory protein-1alpha (MIP-1alpha), and type I collagen telopeptide, but not parathyroid hormone, calcitriol or parathyroid hormone-related peptide at diagnosis, suggesting local osteoclastic hypercalcemia in this case. By reverse transcription polymerase chain reaction (RT-PCR) analysis, we found predominant expression of mRNA for MIP-1alpha in addition to those for receptor-activator of nuclear-factor kappa B ligand (RANKL), TNF-alpha, and IL-6 in lymphoma cells obtained from the patient. Furthermore, recombinant MIP-1alpha significantly stimulated (3)H-thymidine uptake by isolated MCL cells in vitro. Treatment with intravenous fluids, bisphosphonate, and methylprednisolone followed by combination chemotherapy promptly corrects the hypercalcemia and successfully induced complete remission, which was accompanied by a decrease of these cytokines in the serum, including MIP-1alpha. In the present case, MIP-1alpha, an osteoclast-activating factor produced by mantle lymphoma cells, may contribute to the development of hypercalcemia. It likely acts through RANKL expression in tumor cells and/or stroma cells, as indicated in multiple myeloma (MM) and adult T-cell leukemia/lymphoma (ATLL). Furthermore, MIP-1alpha is also involved in the development of an aggressive phenotype on MCL by stimulating proliferation of these lymphoma cells. In summary, the present study demonstrated that MIP-1alpha is an important factor in the development of both hypercalcemia and an aggressive phenotype in some types of B-cell lymphoma.
authors.affiliation: Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan. nhattor@med.showa-u.ac.jp
authors.forename: Norimichi
authors.initials: N
authors.lastname: Hattori
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Nakamaki
authors.forename: Hirotsugu
authors.initials: H
authors.lastname: Ariizumi
authors.forename: Mayumi
authors.initials: M
authors.lastname: Homma
authors.forename: Toshiko
authors.initials: T
authors.lastname: Yamochi-Onizuka
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Ota
authors.forename: Shigeru
authors.initials: S
authors.lastname: Tomoyasu
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D054405:Chemokine CCL3 / Q000097:blood* / Q000235:genetics; D006801:Humans; D006934:Hypercalcemia / Q000150:complications / Q000378:metabolism*; D020522:Lymphoma, Mantle-Cell / Q000150:complications / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D008297:Male; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D054405:Chemokine CCL3